ChromaDose brings together doctors, scientists, researchers, engineers, patients, and parents to develop a bedside drug monitoring technology, enabling optimal dosing in childhood cancer.  

Our vision is for all children receiving anthracycline anti-cancer medicines to benefit from the safety and effectiveness of personalised treatment. This helps reduce some children not getting enough chemotherapy, and other children receiving too much chemotherapy, both of which have serious consequences.

1. The healthcare professional takes the ChromaDose equipment to the patient bedside

2. The technology will guide the healthcare professional in taking a few drops of blood at different times.

3. Blood samples are collected from the child or baby undergoing chemotherapy treatment.

4. The blood sample is put into a cartridge that prevents cross-contamination.

5. The cartridge is put into the ChromaDose machine. 

6. The machine will automatically and accurately measure the amount of drug within each blood drop to generate a patient's drug exposure within 30-minutes.

7. The healthcare professional adjusts the amount of chemotherapy given according to the data provided by ChromaDose.

What is the impact?

There are over 500,000 survivors of childhood cancer in Europe, of which 1 in 4 will suffer from a treatment related side effect in adulthood.

Safer and more effective dosing during treatment is an important step in improving the health outcomes and experiences of patients, reducing the burden on societies and elevating the standard of care for children with cancer.